Introgen Advexin Data Strengthens Biomarker Case In Head And Neck Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
BLA filing for the p53 tumor suppressor remains on track for the second quarter, Medical and Scientific Affairs VP Sobol tells “The Pink Sheet” DAILY.
You may also be interested in...
Introgen Restructures To Ready For Advexin Approval Process
New manufacturing unit could profit from pickup in gene-therapy business.
Introgen Restructures To Ready For Advexin Approval Process
New manufacturing unit could profit from pickup in gene-therapy business.
Introgen Files Advexin For Head And Neck Cancer In U.S., EU
Biotech says it hopes to follow the Idec/Rituxan model in bringing oncologic gene therapy to the U.S. market.